Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

A Prognostic Scoring System for Patients ≤ 60 Years of Age with Acute Lymphocytic Leukemia in First Relapse.

Anjali Advani, MD, Tao Jin, Brian J. Bolwell, MD, Edward A. Copelan, MD, Mikkael A Sekeres, MD, MS, Ronald Sobecks, MD, Shawnda Sungren, Melissa Yurch, Matt Kalaycio, MD

Blood (2008) 112 (11): 901.

https://doi.org/10.1182/blood.V112.11.901.901

Published: 2008

Journal Articles

A Phase 1 Trial of Imatinib Mesylate with Daunorubicin and Cytarabine for Patients with C-Kit Positive Relapsed AML.

Anjali Advani, MD, Edward A. Copelan, MD, Ronald Sobecks, MD, Mikkael A Sekeres, MD, MS, Jennifer Bates, Mary Lynn Rush, Barbara Tripp, Elysa Noon, PhD, Matthew Howard, MD, Tao Jin, Eric Hsi, MD, Matt Kalaycio, MD

Blood (2008) 112 (11): 955.

https://doi.org/10.1182/blood.V112.11.955.955

Published: 2008

Journal Articles

Histone H4 Acetylation as a Prognostic Factor for Patients with Acute Lymphocytic Leukemia in First Relapse.

Anjali Advani, MD, Sarah Gibson, MD, Elizabeth Douglas, MD, Tao Jin, Matt Kalaycio, MD, Edward A. Copelan, MD, Mikkael A Sekeres, MD, MS, Ronald Sobecks, MD, Shawnda Sungren, Eric Hsi, MD

Blood (2008) 112 (11): 1482.

https://doi.org/10.1182/blood.V112.11.1482.1482

Published: 2008

Journal Articles

OCT-2 Expression and OCT-2/BOB.1 Co-Expression Predict Prognosis in Patients with Newly Diagnosed Acute Myelogenous Leukemia.

Kathleen Lim, MD, Sarah Gibson, MD, Tao Jin, Eric Hsi, MD, Matt Kalaycio, MD, Edward A. Copelan, MD, Mikkael A. Sekeres, MD, MS, Ronald Sobecks, MD, Anjali Advani, MD

Blood (2008) 112 (11): 1486.

https://doi.org/10.1182/blood.V112.11.1486.1486

Published: 2008

Journal Articles

Are Mast Cells a Biologic Predictor of Outcome in Follicular Lymphoma?

Matthew T Howard, Brad Pohlman, Tao Jin, Eric Hsi

Blood (2008) 112 (11): 3772.

https://doi.org/10.1182/blood.V112.11.3772.3772

Published: 2008

Journal Articles

Histone H4 Acetylation Is Associated with Improved Relapse-Free Survival in Newly Diagnosed Patients with Acute Lymphoblastic Leukemia (ALL) Less Than 60 Years of Age without Poor Risk Cytogenetics.

Anjali S. Advani, MD, Sarah Gibson, MD, Tao Jin, MS, Matt Kalaycio, MD, Ronald Sobecks, MD, Mikkael A. Sekeres, MD, Ed Copelan, MD, Shawnda Sungren, BBA, Eric D. Hsi, MD

Blood (2007) 110 (11): 2798.

https://doi.org/10.1182/blood.V110.11.2798.2798

Published: 2007

Journal Articles

Risk Factors and Outcomes for Relapse after Autologous Stem Cell Transplantation for Hodgkin Lymphoma.

Robert M. Dean, MD, John W. Sweetenham, MD, Tao Jin, PhD, Stacey Brown, MS, Brad Pohlman, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Steve Andresen, MD, Edward A. Copelan, MD, Brian J. Bolwell, MD

Blood (2007) 110 (11): 1903.

https://doi.org/10.1182/blood.V110.11.1903.1903

Published: 2007

Journal Articles

When May Patients Be Considered Cured after Autografting for Hodgkin Lymphoma?.

Robert M. Dean, MD, John W. Sweetenham, MD, Tao Jin, PhD, Stacey Brown, MS, Brad Pohlman, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Steve Andresen, MD, Edward Copelan, MD, Brian J. Bolwell, MD

Blood (2007) 110 (11): 1909.

https://doi.org/10.1182/blood.V110.11.1909.1909

Published: 2007

Journal Articles

Time to Post-Remission Therapy (PRT) Is an Independent Prognostic Factor for Relapse and Overall Survival in Adults with Acute Lymphocytic Leukemia (ALL).

Anjali Advani, MD, Tao Jin, MS, Ramon Tiu, MD, Giridharan Ramsingh, MD, Christopher Lowe, PharmD, Wael Saber, MD, Ronald Sobecks, MD, Mikkael Sekeres, MD, Shawnda Sungren, BBA, Matt Kalaycio, MD

Blood (2006) 108 (11): 1883.

https://doi.org/10.1182/blood.V108.11.1883.1883

Published: 2006

Journal Articles

Blasts Express Phospho-Akt in the Majority of Adult Patients with Acute Lymphocytic Leukemia (ALL).

Anjali S. Advani, MD, Sarah Gibson, MD, Tao Jin, MS, Ramon Tiu, MD, Giridharan Ramsingh, MD, Matt Kalaycio, MD, Brian Bolwell, MD, Ronald Sobecks, MD, Mikkael Sekeres, MD, Shawnda Sungren, BBA, Eric D. Hsi, MD

Blood (2006) 108 (11): 1846.

https://doi.org/10.1182/blood.V108.11.1846.1846

Published: 2006

Journal Articles

Chemotherapy-Related Amenorrhea (CRA) among Premenopausal Patients Treated for Acute Leukemia.

Suzanne R. Fanning, DO, Tao Jin, MS, Joanne M. Hilden, MD, Anjali Advani, MD, Matt Kalaycio, MD, Alan E. Lichtin, MD, Mikkael A. Sekeres, MD, MS, Ronald Sobecks, MD, Halle C.F. Moore, MD

Blood (2006) 108 (11): 3315.

https://doi.org/10.1182/blood.V108.11.3315.3315

Published: 2006

Journal Articles

c-Kit (CD117) Expression Is a Poor Prognostic Factor for Relapse and Overall Survival in Patients with Newly Diagnosed AML.

Cristina Rodriguez, MD, Tao Jin, MS, Rony Abou Jawde, MD, Wael Saber, MD, Rachid Baz, MD, Eric His, MD, Matt Kalaycio, MD, Ronald Sobecks, MD, Mikkael Sekeres, MD, Anjali Advani, MD

Blood (2006) 108 (11): 4510.

https://doi.org/10.1182/blood.V108.11.4510.4510

Published: 2006

Journal Articles

Double Negative T Cells Influence TCR VB Variablity to Induce Allotolerance.

Zachariah A. McIver, DO, Marcin Wlodarski, MD, Jennifer Powers, BS, Christine O’Keefe, PhD, Tao Jin, MS, Ronald Sobecks, MD, Brian J. Bolwell, MD, Jaroslaw P. Maciejewski, MD, PhD

Blood (2006) 108 (11): 759.

https://doi.org/10.1182/blood.V108.11.759.759

Published: 2006

Journal Articles

Immunohistochemical Expression of CD10, BCL6, and MUM1 in Primary Nodal Diffuse Large B-Cell Lymphoma: MUM1 Expression Alone (but Not Germinal Center B-Cell Immunophenotype) Is an Independent Prognostic Factor.

Nicholas Wongchaowart, MD, Ena Segota, MD, Tao Jin, MS, Brad Pohlman, MD, Eric D. Hsi, MD

Blood (2005) 106 (11): 4706.

https://doi.org/10.1182/blood.V106.11.4706.4706

Published: 2005

Journal Articles

CD117 Expression Is a Poor Prognostic Factor (PF) for Progression Free Survival (PFS) and Freedom from Progression (FFP) in Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML).

Wael Saber, MD, Rony Abou-Jawde, MD, Eric Hsi, MD, Tao Jin, MS, Matt Kalaycio, MD, Ronald Sobecks, MD, Mikkael Sekeres, MD, Brad Pohlman, MD, Barbara L. Tripp, RN, Anjali Advani, MD

Blood (2005) 106 (11): 3292.

https://doi.org/10.1182/blood.V106.11.3292.3292

Published: 2005

Journal Articles

Non-Myeloablative vs. Conventional Allogeneic Hematopoietic Stem Cell Transplantation for Lymphoma.

Brad Pohlman, MD, Tao Jin, MS, Elizabeth Kuczkowski, Stacey Brown, Ronald Sobecks, MD, Matt Kalaycio, MD, Steven Andresen, MD, Brian J. Bolwell, MD

Blood (2005) 106 (11): 1132.

https://doi.org/10.1182/blood.V106.11.1132.1132

Published: 2005

NARROW

A Prognostic Scoring System for Patients ≤ 60 Years of Age with Acute Lymphocytic Leukemia in First Relapse.

A Phase 1 Trial of Imatinib Mesylate with Daunorubicin and Cytarabine for Patients with C-Kit Positive Relapsed AML.

Histone H4 Acetylation as a Prognostic Factor for Patients with Acute Lymphocytic Leukemia in First Relapse.

OCT-2 Expression and OCT-2/BOB.1 Co-Expression Predict Prognosis in Patients with Newly Diagnosed Acute Myelogenous Leukemia.

Are Mast Cells a Biologic Predictor of Outcome in Follicular Lymphoma?

Histone H4 Acetylation Is Associated with Improved Relapse-Free Survival in Newly Diagnosed Patients with Acute Lymphoblastic Leukemia (ALL) Less Than 60 Years of Age without Poor Risk Cytogenetics.

Risk Factors and Outcomes for Relapse after Autologous Stem Cell Transplantation for Hodgkin Lymphoma.

When May Patients Be Considered Cured after Autografting for Hodgkin Lymphoma?.

Time to Post-Remission Therapy (PRT) Is an Independent Prognostic Factor for Relapse and Overall Survival in Adults with Acute Lymphocytic Leukemia (ALL).

Blasts Express Phospho-Akt in the Majority of Adult Patients with Acute Lymphocytic Leukemia (ALL).

Chemotherapy-Related Amenorrhea (CRA) among Premenopausal Patients Treated for Acute Leukemia.

c-Kit (CD117) Expression Is a Poor Prognostic Factor for Relapse and Overall Survival in Patients with Newly Diagnosed AML.

Double Negative T Cells Influence TCR VB Variablity to Induce Allotolerance.

Immunohistochemical Expression of CD10, BCL6, and MUM1 in Primary Nodal Diffuse Large B-Cell Lymphoma: MUM1 Expression Alone (but Not Germinal Center B-Cell Immunophenotype) Is an Independent Prognostic Factor.

CD117 Expression Is a Poor Prognostic Factor (PF) for Progression Free Survival (PFS) and Freedom from Progression (FFP) in Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML).

Non-Myeloablative vs. Conventional Allogeneic Hematopoietic Stem Cell Transplantation for Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only